About

Harry Peters has been working as a specialist in the use of lactose in pharmaceutical applications for more than 15 years. In the last six years at DFE Pharma, he has further specialised in the dry powder inhalation field. Mr Peters is Senior Product Application Specialist (Inhalation), having started working as R&D manager and Product Application Specialist for inhalation grade lactose. He advises formulators of dry powder inhalers about the use of inhalation grade lactose.

Contributions

PULMONARY

COLLABORATION AIMS TO ACCELERATE DEVELOPMENT PROCESS IN DPI FORMULATION

Harry Peters explains how the collaboration between DFE Pharma, Hosokawa Micron and Harro Höfliger can help manufacturers save time and money in the development process for dry powder inhalers, enabling them to tackle unmet needs and unleash the potential of the significant market opportunity presented by dry powder inhalers.

More contributions

RESPIRATORY

PRACTICAL INSIGHTS INTO LACTOSE-BASED DPI FORMULATIONS, WITH & WITHOUT MAGNESIUM STEARATE

Partners DFE Pharma, Hosokawa Micron and Harro Höfliger describe their unique multidisciplinary study into lactose-based DPI formulations including magnesium stearate, whose findings will give generic players a head-start in the development process so that they can tap into this rapidly growing market. The three companies announce that they will be presenting the key insights from their research to interested parties during a joint webinar on the June 30th, 2020.

EXPERT VIEW

SELECTION OF EXCIPIENTS FOR DRY POWDER INHALERS

Harry Peters and Gerald Hebbink explain how, because dry powder inhalers need a carrier to help with ensuring the drug is effectively delivered, interest has been focused on developing inhalation-grade lactose for this purpose.